Table 1 Clinical characteristics of the study population
N, % | The entire cohort (N = 626) | The training cohort (N = 418) | The validation cohort (N = 208) |
|---|---|---|---|
Sex, Male/Female | 468/158 (74.8/25.2) | 308/110 (73.7/26.3) | 160/48 (76.9/23.1) |
Age, < 60 /≥60 years | 419/207 (66.9/33.1) | 282/136 (67.5/32.5) | 137/71 (65.9/34.1) |
Co-morbid illness, No/Yes | 473/153 (75.6/24.4) | 319/99 (75.4/24.6) | 154/54 (74.0/26.0) |
TBIL, ≤ 23 />23 µmol/L | 477/149 (76.2/23.8) | 364/115 (76.0/24.0) | 162/46 (77.9/22.1) |
ALB, ≤ 35 />35 g/L | 565/61 (90.3/9.7) | 376/42 (90.0/10.0) | 189/19 (90.9/9.1) |
ALT, ≤ 40 />40 IU/L | 427/199 (68.2/31.8) | 285/133 (68.2/31.8) | 142/66 (68.3/31.7) |
AST, ≤ 40 />40 U/L | 489/140 (77.6/22.4) | 319/99 (76.3/23.7) | 142/66 (74.4/25.6) |
GGT, ≤ 60 />60 U/L | 293/333 (46.8/53.2) | 196/222 (46.9/53.1) | 97/111 (46.6/53.4) |
PT, ≤ 13 />13 S | 315/311 (50.3/49.7) | 210/208 (50.2/49.8) | 105/103 (50.5/49.5) |
Platelet count, ≤ 100 />100 × 109/L | 567/59 (90.6/9.4) | 376/42 (90.0/10.0) | 191/17 (91.8/8.2) |
AFP level, ≤ 20 />20 ug/L | 466/160 (74.4/25.6) | 314/104 (75.1/24.9) | 152/56 (73.1/26.9) |
CA19-9 level, ≤ 200 />200 U/mL | 543/83 (86.7/13.3) | 365/53 (87.3/12.7) | 178/30 (85.6/14.4) |
CEA level, ≤ 10 />10 ug/L | 538/88 (85.9/14.1) | 359/59 (85.9/14.1) | 179/29 (86.1/13.9) |
Maximum tumor size, ≤ 5 />5 cm | 241/385 (38.5/61.5) | 152/266 (36.4/63.6) | 89/119 (42.8/57.2) |
Tumor number, 1 /≥2 | 528/98 (84.3/15.7) | 358/60 (85.6/14.4) | 170/38 (81.7/18.3) |
Preoperative image lymph node metastasis, No/Yes | 544/82 (86.9/13.1) | 368/50 (88.0/12.0) | 176/32 (84.6/15.4) |
Cirrhosis, No/Yes | 454/172 (72.5/27.5) | 303/115 (72.5/27.5) | 151/57 (72.6/27.4) |
Type of resection, anatomical | 115 (18.4) | 73 (17.5) | 42 (20.2) |
Major hepatectomy, ≥ 3 segments | 226 (36.2) | 158 (37.9) | 68 (35.2) |
MVI, No/Yes | 519/107 (82.9/17.1) | 352/66 (84.2/15.8) | 167/41 (80.3/19.7) |